Literature DB >> 17853490

Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families.

Nardo Nardocci1, Giovanna Zorzi, Chiara Barzaghi, Federica Zibordi, Claudia Ciano, Daniele Ghezzi, Barbara Garavaglia.   

Abstract

Myoclonus-dystonia syndrome (MDS) is an inherited movement disorder with clinical and genetic heterogeneity. The epsilon sarcoglycan (SGCE) gene is an important cause of MDS. We report the results of a clinical and genetic study of 20 patients from 11 families. We disclosed six novel and two previously described mutations in nine families. The majority of patients had a phenotype of myoclonus and dystonia in combination, but clinical findings considered atypical, such a very early onset, distal myoclonus, and legs involvement, were detected in a significant proportion of cases. The disease course was variable, from progression to spontaneous remission of the motor symptoms. There were no obvious differences between mutation-positive and -negative cases. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17853490     DOI: 10.1002/mds.21715

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Treatment of myoclonus-dystonia syndrome with tetrabenazine.

Authors:  Angelo Y Luciano; H A Jinnah; Ronald F Pfeiffer; Daniel D Truong; Martha A Nance; Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2014-10-05       Impact factor: 4.891

2.  Dilated cardiomyopathy mutations in δ-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability.

Authors:  Matthew D Campbell; Marc Witcher; Anoop Gopal; Daniel E Michele
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-03-11       Impact factor: 4.733

3.  SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis?

Authors:  Katja Ritz; Barbera Dc van Schaik; Marja E Jakobs; Antoine H van Kampen; Eleonora Aronica; Marina A Tijssen; Frank Baas
Journal:  Eur J Hum Genet       Date:  2010-12-15       Impact factor: 4.246

Review 4.  What's new in dystonia?

Authors:  Vicki Shanker; Susan B Bressman
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

5.  Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation.

Authors:  Kristoffer Haugarvoll; Charalampos Tzoulis; Gia T Tran; Bjørn Karlsen; Bernt A Engelsen; Per M Knappskog; Laurence A Bindoff
Journal:  J Neurol       Date:  2013-12-03       Impact factor: 4.849

Review 6.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

7.  Locus Pocus.

Authors:  H A Jinnah
Journal:  Mov Disord       Date:  2016-08-22       Impact factor: 10.338

8.  Cryptic 7q21 and 9p23 deletions in a patient with apparently balanced de novo reciprocal translocation t(7;9)(q21;p23) associated with a dystonia-plus syndrome: paternal deletion of the epsilon-sarcoglycan (SGCE) gene.

Authors:  C Bonnet; M-J Grégoire; M Vibert; E Raffo; B Leheup; P Jonveaux
Journal:  J Hum Genet       Date:  2008-07-24       Impact factor: 3.172

Review 9.  Movement disorders in children: recent advances in management.

Authors:  Emilio Fernández-Alvarez
Journal:  Indian J Pediatr       Date:  2009-05-24       Impact factor: 1.967

10.  Familial cortical myoclonus with a mutation in NOL3.

Authors:  Jonathan F Russell; Jamie L Steckley; Giovanni Coppola; Angelika F G Hahn; MacKenzie A Howard; Zachary Kornberg; Alden Huang; Seyed M Mirsattari; Barry Merriman; Eric Klein; Murim Choi; Hsien-Yang Lee; Andrew Kirk; Carol Nelson-Williams; Gillian Gibson; Scott C Baraban; Richard P Lifton; Daniel H Geschwind; Ying-Hui Fu; Louis J Ptáček
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.